Provista Recruits Women for Breast Cancer Blood Test

Provista Diagnostics has completed enrollment in a second cohort of a study of its protein-based biomarker blood test to aid in the detection of breast cancer.

The company enrolled 509 women who will be monitored for six or 12 months as part of a randomized trial seeking to validate its blood-based biomarker panel assay in conjunction with imaging.

The women were enrolled in randomized tests at 12 breast cancer centers across the U.S. Blood was drawn to analyze protein biomarkers and evaluated by a proprietary algorithm to yield a unique protein signature to determine if such signatures can differentiate malignant from benign tumors.

The New York company focuses on developing and commercializing blood-based diagnostic, prognostic and monitoring tests for women’s cancers. — John Bechtel